Cytotoxic and molecular chemotherapy for high-grade glioma: an emerging strategy for the future

Bibliography

• TEWS DS, NISSEN A, KULGEN C, GAUMANN AK: Drug resistance-associated factors in primary and secondary glioblastomas and their precursor tumors. J. Neurooncol. (2000) 50(3):227-237.
   PubMed Web of Science ®Google Scholar
• MACDONALD DR, CASCINO TL, SCHOLD SC Jr, CAIRNCROSS JG: Response criteria for Phase II studies of supratentorial malignant glioma. J. Clin. Oncol. (1990) 8(7):1277-1280.
   PubMed Web of Science ®Google Scholar
• LEVIN VA, STEARNS J, BYRD A, FINN A, WEINKAM RJ: The effect of phenobarbital pretreatment on the antitumor activity of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) and 1-(2-chloroethyl)-3-(2,6-dioxo-3-piperidyl-1-nitrosourea (PCNU), and on the plasma pharmacokinetics and biotransformation of BCNU. J. Pharmacol. Exp. Ther. (1979) 208(1):1-6.
   PubMed Web of Science ®Google Scholar
• WALKER MD, GREEN SB, BYAR DP et al.: Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N. Engl. J. Med. (1980) 303(23):1323-1329.
   PubMed Web of Science ®Google Scholar
• GREEN SB, BYAR DP, WALKER MD et al.: Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. Cancer Treat. Rep. (1983) 67(2):121-132.
   PubMedGoogle Scholar
• MEDICAL RESEARCH COUNCIL BRAIN TUMOR WORKING PARTY: Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial. J. Clin. Oncol. (2001) 19(2):509-518.
   PubMed Web of Science ®Google Scholar
• STENNING SP, FREEDMAN LS, BLEEHEN NM: An overview of published results from randomized studies of nitrosoureas in primary high grade malignant glioma. Br. J. Cancer (1987) 56(1):89-90.
   PubMed Web of Science ®Google Scholar
• FINE HA, DEAR KB, LOEFFLER JS, BLACK PM, CANELLOS GP: Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer (1993) 71(8):2585-2597.
   PubMed Web of Science ®Google Scholar
• DEANGELIS LM, BURGER PC, GREEN SB, CAIRNCROSS JG: Malignant glioma: who benefits from adjuvant chemotherapy? Ann. Neurol. (1998) 44(4):691-695.
   PubMed Web of Science ®Google Scholar
• CAIRNCROSS JG, MACDONALD DR: Successful chemotherapy for recurrent malignant oligodendroglioma. Ann. Neurol. (1988) 23(4):360-364.
   PubMed Web of Science ®Google Scholar
• MACDONALD DR, GASPAR LE, CAIRNCROSS JG: Successful chemotherapy for newly diagnosed aggressive oligodendroglioma. Ann. Neurol. (1990) 27(5):573-574.
   PubMed Web of Science ®Google Scholar
• GLASS J, HOCHBERG FH, GRUBER ML et al.: The treatment of oligodendrogliomas and mixed oligodendroglioma-astrocytomas with PCV chemotherapy. J. Neurosurg. (1992) 76(5):741-745.
   PubMed Web of Science ®Google Scholar
• CAIRNCROSS G, MACDONALD D, LUDWIN S et al.: Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. (1994) 12(10):2013-2021.
   PubMed Web of Science ®Google Scholar
• KIM L, HOCHBERG FH, THORNTON AF et al.: Procarbazine, lomustine, and vincristine (PCV) chemotherapy for grade III and grade IV oligoastrocytomas. J. Neurosurg. (1996) 85(4):602-607.
   PubMed Web of Science ®Google Scholar
• VAN DEN BENT MJ, KROS JM, HEIMANS JJ et al.: Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group. Neurology (1998) 51(4):1140-1145.
   PubMed Web of Science ®Google Scholar
• YUNG WK, PRADOS MD, YAYA-TUR R et al.: Multicenter Phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J. Clin. Oncol. (1999) 17(9):2762-2771.
   PubMed Web of Science ®Google Scholar
• CAIRNCROSS JG, UEKI K, ZLATESCU MC et al.: Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J. Natl. Cancer Inst. (1998) 90(19):1473-1479.
   PubMed Web of Science ®Google Scholar
• SMITH JS, PERRY A, BORELL TJ et al.: Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J. Clin. Oncol. (2000) 18(3):636-645.
   PubMed Web of Science ®Google Scholar
• INO Y, ZLATESCU MC, SASAKI H et al.: Long survival and therapeutic responses in patients with histologically disparate high-grade gliomas demonstrating chromosome 1p loss. J. Neurosurg. (2000) 92(6):983-990.
   PubMedGoogle Scholar
• BRADA M, HOANG-XUAN K, RAMPLING R et al.: Multicenter Phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann. Oncol. (2001) 12(2):259-266.
   PubMed Web of Science ®Google Scholar
• YUNG WK, ALBRIGHT RE, OLSON J et al.: A Phase II study of temozolomide versus procarbazine in patients with glioblastoma multiforme at first relapse. Br. J. Cancer (2000) 83(5):588-593.
   PubMed Web of Science ®Google Scholar
• CHANG SM, THEODOSOPOULOS P, LAMBORN K et al.: Temozolomide in the treatment of recurrent malignant glioma. Cancer (2004) 100(3):605-611.
   PubMed Web of Science ®Google Scholar
• BRANDES AA, TOSONI A, AMISTA P et al.: How effective is BCNU in recurrent glioblastoma in the modern era? A Phase II trial. Neurology (2004) 63(7):1281-1284.
   PubMed Web of Science ®Google Scholar
• OSOBA D, BRADA M, YUNG WK, PRADOS M: Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme. J. Clin. Oncol. (2000) 18(7):1481-1491.
   PubMed Web of Science ®Google Scholar
• STUPP R, DIETRICH PY, OSTERMANN KRALJEVIC S et al.: Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J. Clin. Oncol. (2002) 20(5):1375-1382.
   PubMed Web of Science ®Google Scholar
• STUPP R, MASON WP, VAN DEN BENT MJ et al.: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. (2005) 352(10):987-996.
   PubMed Web of Science ®Google Scholar
• COHEN MH, JOHNSON JR, PAZDUR R: Food and Drug Administration Drug approval summary: temozolomide plus radiation therapy for the treatment of newly diagnosed glioblastoma multiforme. Clin. Cancer Res. (2005) 11(19 Pt 1):6767-6771.
   PubMed Web of Science ®Google Scholar
• VAN DEN BENT MJ, TAPHOORN MJ, BRANDES AA et al.: Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. J. Clin. Oncol. (2003) 21(13):2525-2528.
   PubMed Web of Science ®Google Scholar
• VAN DEN BENT MJ, CHINOT O, BOOGERD W et al.: Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group Phase II study 26972. Ann. Oncol. (2003) 14(4):599-602.
   PubMed Web of Science ®Google Scholar
• CHINOT OL, HONORE S, DUFOUR H et al.: Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy. J. Clin. Oncol. (2001) 19(9):2449-2455.
   PubMed Web of Science ®Google Scholar
• FRIEDMAN HS, PETROS WP, FRIEDMAN AH et al.: Irinotecan therapy in adults with recurrent or progressive malignant glioma. J. Clin. Oncol. (1999) 17(5):1516-1525.
   PubMed Web of Science ®Google Scholar
• MATHIJSSEN RH, SPARREBOOM A, DUMEZ H, VAN OOSTEROM AT, DE BRUIJN EA: Altered irinotecan metabolism in a patient receiving phenytoin. Anticancer Drugs (2002) 13(2):139-140.
   PubMedGoogle Scholar
• HARE CB, ELION GB, HOUGHTON PJ et al.: Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against pediatric and adult central nervous system tumor xenografts. Cancer Chemother. Pharmacol. (1997) 39(3):187-191.
   PubMed Web of Science ®Google Scholar
• CHAMBERLAIN MC: Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme. J. Neurooncol. (2002) 56(2):183-188.
   PubMed Web of Science ®Google Scholar
• RAYMOND E, FABBRO M, BOIGE V et al.: Multicentre Phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naive patients with glioblastoma. Ann. Oncol. (2003) 14(4):603-614.
   PubMed Web of Science ®Google Scholar
• CLOUGHESY TF, FILKA E, KUHN J et al.: Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen. Cancer (2003) 97(9 Suppl.):2381-2386.
   PubMed Web of Science ®Google Scholar
• BUCKNER JC, REID JM, WRIGHT K et al.: Irinotecan in the treatment of glioma patients: current and future studies of the North Central Cancer Treatment Group. Cancer (2003) 97(9 Suppl.):2352-2358.
   PubMedGoogle Scholar
• GILBERT MR, SUPKO JG, BATCHELOR T et al.: Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma. Clin. Cancer Res. (2003) 9(8):2940-2949.
   PubMed Web of Science ®Google Scholar
• PRADOS MD, YUNG WK, JAECKLE KA et al.: Phase I trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro-oncol. (2004) 6(1):44-54.
   PubMed Web of Science ®Google Scholar
• BATCHELOR TT, LAWSON D, MIKKELSEN T et al.: Phase I/II trial of oxaliplatin in adults with newly diagnosed glioblastoma multiforme: NABTT 9902. Neuro-oncol. (2002) 4(4):364.
   Google Scholar
• DOZ F, BERENS ME, DOUGHERTY DV, ROSENBLUM ML: Comparison of the cytotoxic activities of cisplatin and carboplatin against glioma cell lines at pharmacologically relevant drug exposures. J. Neurooncol. (1991) 11(1):27-35.
   PubMed Web of Science ®Google Scholar
• YUNG WK, MECHTLER L, GLEASON MJ: Intravenous carboplatin for recurrent malignant glioma: a Phase II study. J. Clin. Oncol. (1991) 9(5):860-864.
   PubMed Web of Science ®Google Scholar
• FRANCESCHI E, CAVALLO G, SCOPECE L et al.: Phase II trial of carboplatin and etoposide for patients with recurrent high-grade glioma. Br. J. Cancer (2004) 91(6):1038-1044.
   PubMedGoogle Scholar
• WATANABE K, KANAYA H, FUJIYAMA Y, KIM P: Combination chemotherapy using carboplatin (JM-8) and etoposide (JET therapy) for recurrent malignant gliomas: a Phase II study. Acta Neurochir. (2002) 144(12):1265-1270.
   PubMed Web of Science ®Google Scholar
• JEREMIC B, GRUJICIC D, JEVREMOVIC S et al.: Carboplatin and etoposide chemotherapy regimen for recurrent malignant glioma: a Phase II study. J. Clin. Oncol. (1992) 10(7):1074-1077.
   PubMed Web of Science ®Google Scholar
• NAKAGAWA H, FUJITA T, KUBO S et al.: Difference in CDDP penetration into CSF between selective intraarterial chemotherapy in patients with malignant glioma and intravenous or intracarotid administration in patients with metastatic brain tumor. Cancer Chemother. Pharmacol. (1996) 37(4):317-326.
   PubMed Web of Science ®Google Scholar
• NEWTON HB, PAGE MA, JUNCK L, GREENBERG HS: Intra-arterial cisplatin for the treatment of malignant gliomas. J. Neurooncol. (1989) 7(1):39-45.
   PubMed Web of Science ®Google Scholar
• SHAPIRO WR, GREEN SB, BURGER PC et al.: A randomized comparison of intra-arterial versus intravenous BCNU, with or without intravenous 5-fluorouracil, for newly diagnosed patients with malignant glioma. J. Neurosurg. (1992) 76(5):772-781.
   PubMed Web of Science ®Google Scholar
• ASHBY LS, SHAPIRO WR: Intra-arterial cisplatin plus oral etoposide for the treatment of recurrent malignant glioma: a Phase II study. J. Neurooncol. (2001) 51(1):67-86.
   PubMed Web of Science ®Google Scholar
• NEWTON HB, SLIVKA MA, STEVENS CL et al.: Intra-arterial carboplatin and intravenous etoposide for the treatment of recurrent and progressive non-GBM gliomas. J. Neurooncol. (2002) 56(1):79-86.
   PubMedGoogle Scholar
• FRIEDMAN HS, MCLENDON RE, KERBY T et al.: DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to temodal in newly diagnosed malignant glioma. J. Clin. Oncol. (1998) 16(12):3851-3857.
   PubMed Web of Science ®Google Scholar
• MA J, MURPHY M, O’DWYER PJ et al.: Biochemical changes associated with a multidrug-resistant phenotype of a human glioma cell line with temozolomide-acquired resistance. Biochem. Pharmacol. (2002) 63(7):1219-1228.
   PubMed Web of Science ®Google Scholar
• BELANICH M, PASTOR M, RANDALL T et al.: Retrospective study of the correlation between the DNA repair protein alkyltransferase and survival of brain tumor patients treated with carmustine. Cancer Res. (1996) 56(4):783-788.
   PubMed Web of Science ®Google Scholar
• JAECKLE KA, EYRE HJ, TOWNSEND JJ et al.: Correlation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study. J. Clin. Oncol. (1998) 16(10):3310-3315.
   PubMed Web of Science ®Google Scholar
• ESTELLER M, GARCIA-FONCILLAS J, ANDION E et al.: Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N. Engl. J. Med. (2000) 343(19):1350-1354.
   PubMed Web of Science ®Google Scholar
• GERSON SL: Clinical relevance of MGMT in the treatment of cancer. J. Clin. Oncol. (2002) 20(9):2388-2399.
   PubMed Web of Science ®Google Scholar
• HEGI ME, DISERENS AC, GORLIA T et al.: MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. (2005) 352(10):997-1003.
   PubMed Web of Science ®Google Scholar
• FRIEDMAN HS, DOLAN ME, PEGG AE et al.: Activity of temozolomide in the treatment of central nervous system tumor xenografts. Cancer Res. (1995) 55(13):2853-2857.
   PubMed Web of Science ®Google Scholar
• FELKER GM, FRIEDMAN HS, DOLAN ME, MOSCHEL RC, SCHOLD C: Treatment of subcutaneous and intracranial brain tumor xenografts with O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Chemother. Pharmacol. (1993) 32(6):471-476.
   PubMedGoogle Scholar
• DOLAN ME, PEGG AE: O6-benzylguanine and its role in chemotherapy. Clin. Cancer Res. (1997) 3(6):837-847.
   PubMed Web of Science ®Google Scholar
• FRIEDMAN HS, KOKKINAKIS DM, PLUDA J et al.: Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant glioma. J. Clin. Oncol. (1998) 16(11):3570-3575.
   PubMed Web of Science ®Google Scholar
• FRIEDMAN HS, PLUDA J, QUINN JA et al.: Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. J. Clin. Oncol. (2000) 18(20):3522-3528.
   PubMed Web of Science ®Google Scholar
• QUINN JA, PLUDA J, DOLAN ME et al.: Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. J. Clin. Oncol. (2002) 20(9):2277-2283.
   PubMed Web of Science ®Google Scholar
• QUINN JA, DESJARDINS A, REARDON DA et al.: Phase II trial of temozolomide (temodar) plus O6-benzylguanine in the treatment of patients with temodar-resistent malignant glioma. Neuro-oncol. (2004) 6(4):380. Abstract.
   Google Scholar
• QUINN JA, DESJARDINS A, REARDON DA et al.: Phase I trial of temozolomide (temodar) plus irinotecan plus o6-benzylguanine in the treatment of recurrent or progressive cerebral anaplstic glioma. Neuro-oncol. (2004) 6(4):380.
   Google Scholar
• KREKLAU EL, POLLOK KE, BAILEY BJ et al.: Hematopoietic expression of O(6)-methylguanine DNA methyltransferase-P140K allows intensive treatment of human glioma xenografts with combination O(6)-benzylguanine and 1,3-bis-(2-chloroethyl)-1-nitrosourea. Mol. Cancer Ther. (2003) 2(12):1321-1329. Abstract.
   PubMedGoogle Scholar
• REESE JS, DAVIS BM, LIU L, GERSON SL: Simultaneous protection of G156A methylguanine DNA methyltransferase gene-transduced hematopoietic progenitors and sensitization of tumor cells using O6-benzylguanine and temozolomide. Clin. Cancer Res. (1999) 5(1):163-169.
   PubMed Web of Science ®Google Scholar
• TOLCHER AW, GERSON SL, DENIS L et al.: Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br. J. Cancer (2003) 88(7):1004-1011.
   PubMed Web of Science ®Google Scholar
• BROCK CS, NEWLANDS ES, WEDGE SR et al.: Phase I trial of temozolomide using an extended continuous oral schedule. Cancer Res. (1998) 58(19):4363-4367.
   PubMed Web of Science ®Google Scholar
• KHAN RB, RAIZER JJ, MALKIN MG, BAZYLEWICZ KA, ABREY LE: A Phase II study of extended low-dose temozolomide in recurrent malignant gliomas. Neuro-oncol. (2002) 4(1):39-43.
   PubMed Web of Science ®Google Scholar
• SILVANI A, EOLI M, SALMAGGI A et al.: Phase II trial of cisplatin plus temozolomide, in recurrent and progressive malignant glioma patients. J. Neuro-oncol. (2004) 66(1-2):203-208.
   PubMed Web of Science ®Google Scholar
• BOIARDI A, SILVANI A, CIUSANI E et al.: Fotemustine combined with procarbazine in recurrent malignant gliomas: a Phase I study with evaluation of lymphocyte 06-alkylguanine-DNA alkyltransferase activity. J. Neurooncol. (2001) 52(2):149-156.
   PubMedGoogle Scholar
• BRANDES AA, TURAZZI S, BASSO U et al.: A multidrug combination designed for reversing resistance to BCNU in glioblastoma multiforme. Neurology (2002) 58(12):1759-1764.
   PubMed Web of Science ®Google Scholar
• D’ATRI S, TENTORI L, LACAL PM et al.: Involvement of the mismatch repair system in temozolomide-induced apoptosis. Mol. Pharmacol. (1998) 54(2):334-341.
   PubMed Web of Science ®Google Scholar
• TENTORI L, GRAZIANI G: Chemopotentiation by PARP inhibitors in cancer therapy. Pharmacol. Res. (2005) 52(1):25-33.
   PubMed Web of Science ®Google Scholar
• CURTIN NJ, WANG LZ, YIAKOUVAKI A et al.: Novel poly(ADP-ribose) polymerase-1 inhibitor, AG14361, restores sensitivity to temozolomide in mismatch repair-deficient cells. Clin. Cancer Res. (2004) 10(3):881-889.
   PubMed Web of Science ®Google Scholar
• TENTORI L, LEONETTI C, SCARSELLA M et al.: Brain distribution and efficacy as chemosensitizer of an oral formulation of PARP-1 inhibitor GPI 15427 in experimental models of CNS tumors. Int. J. Oncol. (2005) 26(2):415-422.
   PubMedGoogle Scholar
• CHENG CL, JOHNSON SP, KEIR ST et al.: Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft. Mol. Cancer Ther. (2005) 4(9):1364-1368.
   PubMed Web of Science ®Google Scholar
• ABREY LE, YAHALOM J, DEANGELIS LM: Treatment for primary CNS lymphoma: the next step. J. Clin. Oncol. (2000) 18(17):3144-3150.
   PubMed Web of Science ®Google Scholar
• MCALLISTER LD, DOOLITTLE ND, GUASTADISEGNI PE et al.: Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma. Neurosurgery (2000) 46(1):51-60; discussion 60-51.
   PubMed Web of Science ®Google Scholar
• PRADOS MD, SCHOLD SJS, FINE HA et al.: A randomized, double-blind, placebo-controlled, Phase II study of RMP-7 in combination with carboplatin administered intravenously for the treatment of recurrent malignant glioma. Neuro-oncol. (2003) 5(2):96-103.
   PubMed Web of Science ®Google Scholar
• CASTELLINO RC, ELION GB, KEIR ST et al.: Schedule-dependent activity of irinotecan plus BCNU against malignant glioma xenografts. Cancer Chemother. Pharmacol. (2000) 45(4):345-349.
   PubMedGoogle Scholar
• BRANDES AA, TOSONI A, BASSO U et al.: Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a Phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). J. Clin. Oncol. (2004) 22(23):4779-4786.
   PubMed Web of Science ®Google Scholar
• REARDON DA, QUINN JA, RICH JN et al.: Phase II trial of BCNU plus irinotecan in adults with malignant glioma. Neuro-oncol. (2004) 6(2):134-144.
   PubMed Web of Science ®Google Scholar
• PATEL VJ, ELION GB, HOUGHTON PJ et al.: Schedule-dependent activity of temozolomide plus CPT-11 against a human central nervous system tumor-derived xenograft. Clin. Cancer Res. (2000) 6(10):4154-4157.
   PubMed Web of Science ®Google Scholar
• POURQUIER P, WALTMAN JL, URASAKI Y et al.: Topoisomerase I-mediated cytotoxicity of N-methyl-N′-nitro-N-nitrosoguanidine: trapping of topoisomerase I by the O6-methylguanine. Cancer Res. (2001) 61(1):53-58.
   PubMed Web of Science ®Google Scholar
• REARDON DA, QUINN JA, RICH JN et al.: Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma. Cancer (2005) 104(7):1478-1486.
   PubMed Web of Science ®Google Scholar
• VAN DEN BENT M, DELATTRE J, BRANDES A et al.: First analysis of EORTC trial 26951, a randomized Phase III study of adjuvant PCV chemotherapy in patients with highly anaplastic oligodendroglioma. Proc. Am. Soc. Clin. Oncol. (2005) 23(16s):114s.
   Web of Science ®Google Scholar
• CAIRNCROSS G, SEIFERHELD W, SHAW E et al.: An intergroup randomized controlled clinical trial of chemotherapy plus radiotherapy versus radiotherapy alone for pure and mixed anaplastic oligodendroglioma: initial report of the RTOG. Neuro-oncol. (2004) 6(4):371.
   Google Scholar
• SOFFIETTI R, COSTANZA A, LAGUZZI E, NOBILE M, RUDA R: A Phase II study of first-line temozolomide and second line PCV in recurrent/progressive malignant glioma. Proc. Am. Soc. Clin. Oncol. (2004) 23:125.
   Google Scholar
• NEWTON HB: Molecular neuro-oncology and the development of targeted therapeutic strategies for brain tumors. Part 3: brain tumor invasiveness. Expert Rev. Anti-Cancer Ther. (2004) 4(5):803-821.
   PubMedGoogle Scholar
• NEWTON HB: Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 2: PI3K/Akt/PTEN, mTOR, SHH/PTCH and angiogenesis. Expert Rev. Anti-Cancer Ther. (2004) 4(1):105-128.
   PubMedGoogle Scholar
• NEWTON HB: Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 1: growth factor and ras signaling pathways. Expert Rev. Anti-Cancer Ther. (2003) 3(5):595-614.
   PubMedGoogle Scholar
• FREDERICK L, WANG XY, ELEY G, JAMES CD: Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res. (2000) 60(5):1383-1387.
   PubMed Web of Science ®Google Scholar
• CHAKRAVARTI A, DICKER A, MEHTA M: The contribution of epidermal growth factor receptor (EGFR) signaling pathway to radioresistance in human gliomas: a review of preclinical and correlative clinical data. Int. J. Radiat. Oncol. Biol. Phys. (2004) 58(3):927-931.
   PubMed Web of Science ®Google Scholar
• NAGANE M, COUFAL F, LIN H et al.: A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. Cancer Res. (1996) 56(21):5079-5086.
   PubMed Web of Science ®Google Scholar
• MENDELSOHN J: Targeting the epidermal growth factor receptor for cancer therapy. J. Clin. Oncol. (2002) 20(18 Suppl.):1S-13S.
   PubMed Web of Science ®Google Scholar
• HARJUNPAA A, WIKLUND T, COLLAN J et al.: Complement activation in circulation and central nervous system after rituximab (anti-CD20) treatment of B-cell lymphoma. Leuk. Lymphoma (2001) 42(4):731-738.
   PubMed Web of Science ®Google Scholar
• STRAGLIOTTO G, VEGA F, STASIECKI P et al.: Multiple infusions of anti-epidermal growth factor receptor (EGFR) monoclonal antibody (EMD 55,900) in patients with recurrent malignant gliomas. Eur. J. Cancer (1996) 32A(4):636-640.
   PubMedGoogle Scholar
• FOON KA, YANG XD, WEINER LM et al.: Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. Int. J. Radiat. Oncol. Biol. Phys. (2004) 58(3):984-990.
   PubMed Web of Science ®Google Scholar
• ELLER JL, LONGO SL, HICKLIN DJ, CANUTE GW: Activity of anti-epidermal growth factor receptor monoclonal antibody C225 against glioblastoma multiforme. Neurosurgery (2002) 51(4):1005-1013.
   PubMed Web of Science ®Google Scholar
• BARTH RF, WU G, YANG W et al.: Neutron capture therapy of epidermal growth factor (+) gliomas using boronated cetuximab (IMC-C225) as a delivery agent. Appl. Radiat. Isot. (2004) 61(5):899-903.
   PubMed Web of Science ®Google Scholar
• JOHNS TG, STOCKERT E, RITTER G et al.: Novel monoclonal antibody specific for the de2-7 epidermal growth factor receptor (EGFR) that also recognizes the EGFR expressed in cells containing amplification of the EGFR gene. Int. J. Cancer (2002) 98(3):398-408.
   PubMed Web of Science ®Google Scholar
• MISHIMA K, JOHNS TG, LUWOR RB et al.: Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor. Cancer Res. (2001) 61(14):5349-5354.
   PubMed Web of Science ®Google Scholar
• LIEBERMAN FS, CLOUGHESY TF, FINE H et al.: NABTC Phase I/II trial of ZD-1839 for recurrent malignant gliomas and unresectable meningiomas. Proc. Am. Soc. Clin. Oncol. (2004) 23:109.
   Google Scholar
• HEIMBERGER AB, LEARN CA, ARCHER GE et al.: Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (iressa). Clin. Cancer Res. (2002) 8(11):3496-3502.
   PubMed Web of Science ®Google Scholar
• LEARN CA, HARTZELL TL, WIKSTRAND CJ et al.: Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme. Clin. Cancer Res. (2004) 10(9):3216-3224.
   PubMed Web of Science ®Google Scholar
• UHM JH, BALLMAN KV, GIANNINI C et al.: Phase II Study of ZD 1839 in patients with newly diagnosed grade 4 astrocytoma. Proc. Am. Soc. Clin. Oncol. (2004) 23:1505.
   Google Scholar
• FRANCESCHI E, LONARDI S, TOSONI A et al.: Gefitinib treatment for adults with progressive high-grade glioma: an open label, single arm, Phase II study of the GICNO. J. Clin. Oncol. (2005) 23(16s):1564. Abstract.
   PubMedGoogle Scholar
• RICH JN, REARDON DA, PEERY T et al.: Phase II trial of gefitinib in recurrent glioblastoma. J. Clin. Oncol. (2004) 22(1):133-142.
   PubMed Web of Science ®Google Scholar
• LAL A, GLAZER CA, MARTINSON HM et al.: Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion. Cancer Res. (2002) 62(12):3335-3339.
   PubMed Web of Science ®Google Scholar
• CARLSON BL, SCHROEDER MA, MLADEK AC et al.: Radiosensitization by OSI-774 of serially transplantable human GBM xenografts. Neuro-oncol. (2003) 5(4):321.
   Google Scholar
• HAAS-KOGAN DA, PRADOS MD, TIHAN T et al.: Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J. Natl. Cancer Inst. (2005) 97(12):880-887.
   PubMed Web of Science ®Google Scholar
• YUNG A, VREDENBURGH J, CLOUGHESY TF et al.: Eroltinib HCL for glioblastoma multiforme in first relapse, a Phase II study. Proc. Am. Soc. Clin. Oncol. (2004) 23:120.
   PubMedGoogle Scholar
• VOGELBAUM MA, PEEREBOOM D, STEVENS G, BARNETT G, BREWER C: Phase II study of EGFR kinase inhibitor erlotinib for single agent therapy of recurrent glioblastoma multiforme: interim results. Proc. Am. Soc. Clin. Oncol. (2004) 23:121.
   Google Scholar
• CLOUGHESY TF, YUNG A, VRENDENBURGH J et al.: Phase II study of erlotininb in recurrent GBM: molecular predictors of outcome. Proc. Am. Soc. Clin. Oncol. (2005) 23(16s):115s.
   Google Scholar
• CHINNAIYAN P, HUANG S, VALLABHANENI G et al.: Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (tarceva). Cancer Res. (2005) 65(8):3328-3335.
   PubMed Web of Science ®Google Scholar
• STEA B, FALSEY R, KISLIN K et al.: Time and dose-dependent radiosensitization of the glioblastoma multiforme U251 cells by the EGF receptor tyrosine kinase inhibitor ZD1839 (‘Iressa’). Cancer Lett. (2003) 202(1):43-51.
   PubMed Web of Science ®Google Scholar
• CHAKRAVATI A, SEIFERHELD W, ROBINS HI et al.: An update of Phase I data from RTOG 0211: A Phase I/II clinical study of ZD 1839 (Gefitinib) + radiation for newly diagnosed GBM patients. Neuro-oncol. (2004) 6(4):372.
   Google Scholar
• KRISHNAN S, BROWN P, BALLMAN KV et al.: Phase I trial of erlotinib with radiation therapy in patients with glioblastoma multiforme. Proc. Am. Soc. Clin. Oncol. (2005) 23(16s):117s.
   Google Scholar
• BREWER C, SUH GH, STEVENS G, BARNETT S, TOMS MA: Phase II trial of erlotinib with temozolomide and concurrent radiation therapy in patients with newly-diagnosed glioblastoma multiforme. J. Clin. Oncol. (2005) 23(16s):1567. Abstract.
   Google Scholar
• PLATE KH, BREIER G, FARRELL CL, RISAU W: Platelet-derived growth factor receptor-beta is induced during tumor development and upregulated during tumor progression in endothelial cells in human gliomas. Lab. Invest. (1992) 67(4):529-534.
   PubMed Web of Science ®Google Scholar
• DUNN IF, HEESE O, BLACK PM: Growth factors in glioma angiogenesis: FGFs, PDGF, EGF, and TGFs. J. Neurooncol. (2000) 50(1-2):121-137.
   PubMed Web of Science ®Google Scholar
• ROBERTS WG, WHALEN PM, SODERSTROM E et al.: Antiangiogenic and antitumor activity of a selective PDGFR tyrosine kinase inhibitor, CP-673,451. Cancer Res. (2005) 65(3):957-966.
   PubMed Web of Science ®Google Scholar
• DAI C, CELESTINO JC, OKADA Y et al.: PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo. Genes Dev. (2001) 15(15):1913-1925.
   PubMed Web of Science ®Google Scholar
• LOKKER NA, SULLIVAN CM, HOLLENBACH SJ, ISRAEL MA, GIESE NA: Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors. Cancer Res. (2002) 62(13):3729-3735.
   PubMed Web of Science ®Google Scholar
• TAKEUCHI H, KANZAWA T, KONDO Y, KONDO S: Inhibition of platelet-derived growth factor signalling induces autophagy in malignant glioma cells. Br. J. Cancer (2004) 90(5):1069-1075.
   PubMedGoogle Scholar
• KILIC T, ALBERTA JA, ZDUNEK PR et al.: Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class. Cancer Res. (2000) 60(18):5143-5150.
   PubMed Web of Science ®Google Scholar
• WESTPHAL M, ACKERMANN E, HOPPE J, HERRMANN HD: Receptors for platelet derived growth factor in human glioma cell lines and influence of suramin on cell proliferation. J. Neurooncol. (1991) 11(3):207-213.
   PubMedGoogle Scholar
• VASSBOTN FS, ANDERSSON M, WESTERMARK B, HELDIN CH, OSTMAN A: Reversion of autocrine transformation by a dominant negative platelet-derived growth factor mutant. Mol. Cell. Biol. (1993) 13(7):4066-4076.
   PubMed Web of Science ®Google Scholar
• POTAPOVA O, FAKHRAI H, BAIRD S, MERCOLA D: Platelet-derived growth factor-B/v-sis confers a tumorigenic and metastatic phenotype to human T98G glioblastoma cells. Cancer Res. (1996) 56(2):280-286.
   PubMed Web of Science ®Google Scholar
• RAYMOND E, BRANDES A, VAN OOSTEROM AT et al.: Multicentre Phase II study of imatinib mesylate in patients with recurrent glioblastoma: an EORTC: NDDG/BTG Intergroup Study. Proc. Am. Soc. Clin. Oncol. (2004) 23:107.
   Google Scholar
• DRESEMANN G: Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient series. Ann. Oncol. (2005) 16(10):1702-1708.
   PubMed Web of Science ®Google Scholar
• RICH J, VRENDENBURGH J, DESJARDINS A et al.: Efficacy of imatinib mesylate plus hyroxyurea in the treatment of recurrent malignant glioma: Phase II Study results. Proc. Am. Soc. Clin. Oncol. (2005) 23:117s.
   Google Scholar
• VAN DEN BENT M, BRANDES A, FRENAY M et al.: Multicentre Phase II study of imatinib mesylate in patients with recurrent anaplastic oligodendroglioma/mixed oligoastrocytoma and anaplastic astrocytoma/low-grade astrocytoma: an EORTC New Drug Development Group and Brain Tumor Group study. Proc. Am. Soc. Clin. Oncol. (2005) 23(16S):118s.
   Google Scholar
• HOLDHOFF M, KREUZER KA, APPELT C et al.: Imatinib mesylate radiosensitizes human glioblastoma cells through inhibition of platelet-derived growth factor receptor. Blood Cells Mol. Dis. (2005) 34(2):181-185.
   PubMedGoogle Scholar
• PIETRAS K, RUBIN K, SJOBLOM T et al.: Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res. (2002) 62(19):5476-5484.
   PubMed Web of Science ®Google Scholar
• KUHN J, PRADOS M, ROBINS HI et al.: Phase I trial of R115777 in patients with recurrent malignant gliomas taking enzyme inducing drugs. A North American Brain Tumor Consortium (NABTC) report. Proc. Am. Soc.Clin. Oncol. (2002) 21:86a.
   Google Scholar
• GILBERT MR, HESS KR, GAUPP P et al.: A Phase I study of temozolomide and farnesyltransferase inhibitor, tipifarnib in recurrent glioblastoma: a dose and schedule intensive regimen. Neuro-oncol. (2004) 6(4):375.
   Google Scholar
• CHAKRAVARTI A, ZHAI G, SUZUKI Y et al.: The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas. J. Clin. Oncol. (2004) 22(10):1926-1933.
   PubMed Web of Science ®Google Scholar
• VIGNOT S, FAIVRE S, AGUIRRE D, RAYMOND E: mTOR-targeted therapy of cancer with rapamycin derivatives. Ann. Oncol. (2005) 16(4):525-537.
   PubMed Web of Science ®Google Scholar
• HEIMBERGER AB, WANG E, MCGARY EC et al.: Mechanisms of action of rapamycin in gliomas. Neuro-oncol. (2005) 7(1):1-11.
   PubMedGoogle Scholar
• SARKARIA JN, CARLSON BL, MLADEK AC, ESHLEMAN JS: Rapamycin sensitizes U87 xenografts to fractionated radiation therapy. Neuro-oncol. (2002) 4(4):358.
   Google Scholar
• BUCKNER J, PRADOS M, ROWINSKY EK et al.: A Phase I study of the safety, tolerability and pharmacokinetics of the intravenous CCI-779 given once daily for 5 days every 2 weeks to patients with CNS tumors. Neuro-oncol. (2002) 4(4):365.
   Google Scholar
• CHANG SM, WEN PY, GREENBERG H et al.: Phase I study of CCI-779 in patients with recurrent malignant glioma on enzyme inducing antiepileptic drugs. Neuro-oncol. (2002) 4(4):366.
   Google Scholar
• CHANG SM, WEN P, CLOUGHESY T et al.: Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest. New Drugs (2005) 23(4):357-361.
   PubMed Web of Science ®Google Scholar
• GALANIS E, BUCKNER JC, MAURER MJ et al.: Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J. Clin. Oncol. (2005) 23(23):5294-5304.
   PubMed Web of Science ®Google Scholar
• WESSELING P, RUITER DJ, BURGER PC: Angiogenesis in brain tumors; pathobiological and clinical aspects. J. Neuro-oncol. (1997) 32(3):253-265.
   PubMed Web of Science ®Google Scholar
• NABORS LB, ROSENFELD SS, MIKKELSEN T et al.: NABTT 9911: a Phase I trial of EMD 121974 for treatment of patients with recurrent malignant glioma. Neuro-oncol. (2004) 6(4):379.
   Web of Science ®Google Scholar
• STARK-VANCE V: Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma. Neuro-oncol. (2005) 7(3):369.
   Web of Science ®Google Scholar
• PHUPHANICH S, GROSSMAN S, LESSER G et al.: A Phase I evaluation of the safety and pharmacokinetics of atrasentan in adults with recurrent malignant glioma: preliminary results. Neuro-oncol. (2004) 6(4):380.
   Google Scholar
• FINE H, KIM IH, ROYCE C et al.: A Phase II trial of LY317615 in patients with recurrent high-grade gliomas. Proc. Am. Soc. Clin. Oncol. (2004) 23:109.
   Google Scholar
• FINE H, KIM IH, ROYCE C et al.: A Phase I trial of CC-5103, a potent thalidomide analog, in patients with recurrent high-grade gliomas and other refractory CNS malignancies. Proc. Am. Soc. Clin. Oncol. (2003) 22:105.
   Google Scholar
• GOUDAR RK, SHI Q, HJELMELAND MD et al.: Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. Mol. Cancer Ther. (2005) 4(1):101-112.
   PubMed Web of Science ®Google Scholar
• SAKURADA K, SONODA Y, KITANAKA C, MORI Y, KAYAMA T: Inhibiton of the mammalian target of rapamycin sensitizes glioma cells to anticancer drugs. Neuro-oncol. (2005) 7(3):301.
   Google Scholar
• AKELLA NS, TWIEG DB, MIKKELSEN T et al.: Assessment of brain tumor angiogenesis inhibitors using perfusion magnetic resonance imaging: quality and analysis results of a Phase I trial. J. Magn. Reson. Imaging (2004) 20(6):913-922.
   PubMed Web of Science ®Google Scholar